Backed by OrbiMed, Lilly and now Advantech, China’s InventisBio loads up $70M to propel cancer, metabolic pipeline

Almost two years after bagging a $19 million round for its early-stage R&D amid some sweeping reforms in China’s regulatory world, Shanghai-based InventisBio is back on stage with $70 million in ...

Read the original article: shanghai china - BingNews